| |
The scientific community universally recognizes peer-reviewed literature as the foundation of credible and reproducible research. However, its exponential growth presents a significant challenge for R&D teams in biotech and pharma companies. Learn how to leverage AI to ensure that today’s advancements in drug discovery, clinical trials and regulatory processes are based on data that is up-to-date, validated and meaningful. Download now. 
|
|
Today’s Big NewsJul 16, 2025 |
|
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now. 
|
|
| By Angus Liu The FDA is asking an expert panel to weigh in on “discordant results” from three randomized trials related to Lundbeck and Otsuka's application for a Rexulti combination regimen in PTSD. |
|
|
|
By James Waldron AstraZeneca’s plans to get an amyloidosis blockbuster drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a phase 3 study. |
By Andrea Park Consumers are now almost as likely to say they learn about new medications from advertisements on linear or connected TV as from their doctor, according to a new report. |
By Gabrielle Masson Otsuka Pharmaceutical is putting down $33 million cash for a Swedish biotech’s IL1RAP antibodies designed to treat autoimmune and inflammatory diseases. |
|
Wednesday, July 23, 2025 | 2pm ET / 11am PT The development of radiopharmaceuticals is transforming oncology. Designing successful clinical trials in this space, requires a precise balance of insight, efficiency, and strategy. Join our expert panel to explore the imaging strategies, trial design principles, and regulatory alignment considerations you need to know about. Register now. 
|
|
By Andrea Park In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad spending has crept downward as 2025 has gone on. |
By Fraiser Kansteiner Leading up to the entry of the first Stelara biosimilars in the U.S. at start of 2025, executives at Johnson & Johnson remained steadfast in their belief that they could maintain revenue growth despite the patent expiry. Now, after setting an innovative medicines sales record in the year’s second quarter, it appears J&J’s confidence was well placed. |
By Nick Paul Taylor The National Institutes of Health has fired its chief operating officer amid a probe into whether his wife could have benefited from a $3.3 million contract, according to The Washington Post. |
By Zoey Becker The FDA listed observations at plants run by Sun Pharma, Daewoo Pharmaceutical and Glenmark, citing concerns ranging from mold to quality control issues. |
By Conor Hale “We are not rolling over,” J&J MedTech’s worldwide chairman, Tim Schmid, said on the company’s quarterly earnings call with investors. |
By Andrea Park Fittingly enough, for its third acquisition in as many years, Deerfield Group has picked up Triple Threat Communications. |
By Darren Incorvaia Patients with a mysterious eye pain disease may be one step closer to seeing the first approved treatment for their condition. Okyo Pharma’s urcosimod reduced pain levels by an average of 5.5 on a 10-point scale, hitting the primary endpoint of a phase 2 trial and teeing up a meeting with the FDA about next steps. |
By Kevin Dunleavy In a move to bolster its drug manufacturing capabilities in the United States, Thermo Fisher has purchased a fill-finish and packaging plant from Sanofi in Ridgefield, New Jersey. The terms of the deal were not disclosed. |
By Nick Paul Taylor Real Chemistry has made a flurry of leadership appointments, including hiring JJ Schmuckler from VML to fill a newly created role while also making changes at 21Grams and its communications group. |
By Conor Hale Carlsmed aims to offer personalized fusion procedures by mapping 3D-printed titanium spinal implants to a particular patient’s anatomy. |
By Gabrielle Masson Alphabet spinoff SandboxAQ is teaming up with iOncologi to build a new mRNA vaccine for a common and aggressive brain tumor known as glioblastoma. |
Fierce podcasts Don’t miss an episode |
| Biopharma layoffs have held steady through mid-2025, and in this episode of "The Top Line," we dig into the numbers, closures and policy changes shaping the trend. |
|
|---|
|
|
|
QPS delivers global RWE solutions to support regulatory and drug development goals. With access to diverse data sources and deep regulatory expertise, QPS transforms real-world data into actionable insights. +(2)+(2)+(1)+(1)+(1).png)
|
|
Whitepaper This white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance. Sponsored by: Lonza |
Whitepaper Presented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
| Sheraton Philadelphia Downtown |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
